bioMérieux Expands Customer Services Offer, Appointing James P. Whelan as Executive Vice President, Commercial Services

James Whelan brings extensive experience in e-commerce and in developing diagnostic services for microbiologists and physicians. Before joining bioMérieux, he was president of Clinical Diagnostics at Magellan Biosciences, Inc., a privately held company specialized in rapid point of care and automated microbiology systems. From 2003 to 2007, he worked at Laboratory Corporation of America, building the group’s testing services offer in several key market segments. James Whelan began his career in 1980 at Fisher Scientific International (now Thermo Fisher), where he held sales and management positions for 21 years, including the roles of National Accounts Manager and Senior Vice President of E-commerce.

“Part of our 2015 strategic plan, the goal of building an enhanced suite of services is to help our customers achieve optimal efficiency in the lab,” said Thierry Bernard, Corporate Vice President, bioMérieux Global Commercial Operations. “James’ expertise in diagnostic services will help drive our transformation from a company focused on products, to one focused on providing comprehensive services that enhance patient care.”

Laboratory managers today are faced with significant scientific and technological changes, laboratory consolidation and healthcare budget constraints. They must deal with heightened demand for quality assurance and traceability of samples and results, in addition to an increasingly complex workflow with more limited resources. To build bioMérieux’s complete suite of services, James Whelan and his team will be consulting with customers worldwide to better address their needs.

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached €1.223 billion with 85% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com.

Contacts

Investor Relations

bioMérieux
Isabelle Tongio
Tel: + 33 4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMérieux
Koren Wolman-Tardy
Tel: + 33 4 78 87 20 08
media@biomerieux.com

Fleishman-Hillard
Tim Baker
Tel: +1 216 928-3469
tim.baker@fleishman.com

Image Sept
Albane de La Tour d’Artaise
Tel: +33 1 53 70 74 84
adelatour@image7.fr